UNSPSC 51183616: Insulin peglispro

This classification denotes a peptide hormone C8H16N2O4(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Y83I5F10I, chemically known as poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-methoxy-, 28b-ester with 28b-(n6-carboxy-l-lysine)-29b-l-prolineinsulin (human), but more generally known as insulin peglispro, which bears US NIH Compound Identifier 71301236. Most nations, for tariff and trade purposes, schedule insulin peglispro under HS 29371200 and SITC 54154.

SMILES: As of Q4 2014, INSULIN PEGLISPRO remains US FDA's Preferred Term for this commodity.

UNSPSC 51183616 Insulin peglispro is a Commodity code covering a specific branded diabetes pharmaceutical product. State and local governments procure insulin peglispro primarily through cooperative purchasing agreements that consolidate demand across multiple jurisdictions and establish standardized pricing with authorized pharmaceutical wholesalers. The work involves pharmaceutical manufacturers submitting detailed product specifications, pricing proposals, and compliance certifications to state or multistate procurement offices that manage formularies and drug distribution networks for public health systems, corrections facilities, and other government healthcare operations. Issuing bodies under this code include state departments of administration, multistate cooperative purchasing alliances, and health agencies operating or contracting for pharmacy services.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local government facilities including Oregon. The RFP solicits manufacturers to provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes (NDC), requires vendors to maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and mandates certification of compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Proposals were due March 26, 2026, with awarded vendors to be provided to wholesalers by May 15, 2026 and resulting agreements effective July 1, 2026. Evaluation weighted price competitiveness at 75 percent, with smaller percentages assigned to fixed pricing, administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new responders with optional extensions, while incumbent responders' amendments align with existing agreement expiration through June 30, 2028.